Compare Stocks → A Wave of Creative Destruction Set to Strike June 30 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:ABOSNASDAQ:INMBNASDAQ:OPTNASDAQ:ZURA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.49-3.5%$3.43$1.81▼$11.31$155.01M0.15221,529 shs607,665 shsINMBINmune Bio$8.95-4.7%$10.40$6.50▼$14.74$185.76M1.8990,321 shs117,153 shsOPTOpthea$2.50-3.1%$3.44$1.60▼$4.40$150.66M1.1836,742 shs11,706 shsZURAZura Bio$4.19-8.1%$4.22$2.00▼$13.00$198.79M0.25176,697 shs175,750 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-3.49%-16.44%-25.89%-43.02%-50.40%INMBINmune Bio-4.69%-6.14%-19.95%-26.70%+8.48%OPTOpthea-3.10%-12.89%-25.04%-24.92%-21.63%ZURAZura Bio-8.11%-21.97%-9.70%+29.32%-36.52%Top 5 AI Stocks to Buy for 2024 (Ad)The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest InMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals3.0677 of 5 stars3.55.00.00.03.31.70.6INMBINmune BioN/AN/AN/AN/AN/AN/AN/AN/AOPTOpthea1.5921 of 5 stars3.54.00.00.00.60.80.6ZURAZura Bio2.8024 of 5 stars3.63.00.00.02.94.20.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals3.00Buy$12.00381.93% UpsideINMBINmune BioN/AN/AN/AN/AOPTOpthea3.00Buy$14.00460.00% UpsideZURAZura Bio3.17Buy$18.83349.48% UpsideCurrent Analyst RatingsLatest ZURA, ABOS, INMB, and OPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2024ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/10/2024ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $21.005/3/2024ZURAZura BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.004/1/2024ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$17.00 ➝ $16.003/27/2024ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 6/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AINMBINmune Bio$160K1,106.44N/AN/A$2.07 per share4.32OPTOpthea$110K1,327.27N/AN/A($0.10) per share-25.00ZURAZura BioN/AN/AN/AN/A$1.85 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.06N/AN/AN/AN/A-22.88%-20.82%8/13/2024 (Estimated)INMBINmune Bio-$30.01M-$1.92N/A∞N/A-26,333.59%-86.16%-58.41%8/5/2024 (Estimated)OPTOpthea-$142.52MN/A0.00N/AN/AN/AN/AN/AN/AZURAZura Bio-$69.24MN/A0.00N/AN/AN/A-64.56%-50.33%8/12/2024 (Estimated)Latest ZURA, ABOS, INMB, and OPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2024Q1 2024ABOSAcumen Pharmaceuticals-$0.23-$0.25-$0.02-$0.25N/AN/A 5/9/2024Q1 2024INMBINmune BioN/A-$0.61-$0.61-$0.61N/A$0.01 million 5/9/2024Q1 2024ZURAZura Bio-$0.23-$0.02+$0.21-$0.02N/AN/A3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 million3/26/2024Q4 2023ABOSAcumen Pharmaceuticals-$0.29-$0.29N/A-$0.29N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1230.2030.20INMBINmune BioN/A1.711.71OPTOptheaN/AN/AN/AZURAZura BioN/A6.176.17OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%INMBINmune Bio12.72%OPTOpthea55.95%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.10%INMBINmune Bio35.20%OPTOpthea3.20%ZURAZura Bio15.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals3960.08 million55.81 millionOptionableINMBINmune Bio1119.78 million12.82 millionOptionableOPTOpthea2458.40 million56.53 millionNot OptionableZURAZura Bio1443.59 million36.71 millionNot OptionableZURA, ABOS, INMB, and OPT HeadlinesRecent News About These CompaniesJune 6 at 8:43 AM | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Stake Boosted by Armistice Capital LLCJune 6 at 6:00 AM | businesswire.comZura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and ImmunologyJune 3, 2024 | businesswire.comZura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024May 31, 2024 | zacks.comWall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should KnowMay 31, 2024 | americanbankingnews.comAnalysts Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $18.83May 30, 2024 | americanbankingnews.comZura Bio Limited (NASDAQ:ZURA) Short Interest Up 80.1% in MayMay 29, 2024 | marketbeat.comShort Interest in Zura Bio Limited (NASDAQ:ZURA) Expands By 80.1%May 29, 2024 | businesswire.comZura Bio Announces Participation in June Investor ConferencesMay 28, 2024 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of "Buy" from AnalystsMay 24, 2024 | msn.comZura Bio files to sell 41.6M Class A ordinary shares for holdersMay 24, 2024 | insidertrades.comZura Bio Limited (NASDAQ:ZURA) Director Acquires $496,000.00 in StockMay 24, 2024 | investorplace.com3 Penny Stocks to Buy Now: May 2024May 23, 2024 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Director Van Amstel Arnout Ploos Acquires 80,000 SharesMay 15, 2024 | zacks.comHow Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%May 14, 2024 | zacks.comZura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should KnowMay 10, 2024 | finance.yahoo.comZura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 10, 2024 | marketbeat.comZura Bio (NASDAQ:ZURA) Given New $21.00 Price Target at OppenheimerMay 9, 2024 | investorplace.comZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024May 9, 2024 | finance.yahoo.comZura Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 4, 2024 | msn.comPiper Sandler Initiates Coverage of Zura Bio (ZURA) with Overweight RecommendationMay 3, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Zura Bio (ZURA)New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcumen PharmaceuticalsNASDAQ:ABOSAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.OptheaNASDAQ:OPTOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Zura BioNASDAQ:ZURAZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.